Fibrosis or steatosis: which is the best screening target? Comment on the Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity.
作者信息
Severo Mateus Dornelles
机构信息
Hospital Universitário de Santa Maria Santa MariaRS Brasil Hospital Universitário de Santa Maria, Santa Maria, RS, Brasil.
出版信息
Arch Endocrinol Metab. 2024 Jun 3;68:e240014. doi: 10.20945/2359-4292-2024-0014. eCollection 2024.
Abstract
摘要
相似文献
1
Fibrosis or steatosis: which is the best screening target? Comment on the Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity.纤维化还是脂肪变性：哪个是最佳筛查靶点？对巴西关于超重或肥胖成人代谢功能障碍相关脂肪性肝病（MASLD）筛查、诊断、治疗及随访的循证指南的评论
Arch Endocrinol Metab. 2024 Jun 3;68:e240014. doi: 10.20945/2359-4292-2024-0014. eCollection 2024.
2
Response to the letter to the editor Fibrosis or steatosis: which is the best screening target? Comment on the Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity.对编辑来信的回复：纤维化还是脂肪变性：哪个是最佳筛查靶点？对巴西超重或肥胖成年个体代谢功能障碍相关脂肪性肝病（MASLD）筛查、诊断、治疗及随访的循证指南的评论
Arch Endocrinol Metab. 2024 Jun 3;68:e240093. doi: 10.20945/2359-4292-2024-0093. eCollection 2024.
3
Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).巴西超重或肥胖成人代谢功能障碍相关脂肪性肝病（MASLD）的筛查、诊断、治疗和随访的循证指南：巴西内分泌学会和代谢学会（SBEM）、巴西肝脏学会（SBH）和巴西肥胖与代谢综合征研究协会（Abeso）的联合立场声明。
Arch Endocrinol Metab. 2023 Nov 27;67(6):e230123. doi: 10.20945/2359-4292-2023-0123.
4
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
5
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
Obes Facts. 2024;17(4):374-444. doi: 10.1159/000539371. Epub 2024 Jun 7.
6
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
7
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.在患有脂肪性肝病的个体中，肝脂肪变性而非2型糖尿病、体重指数或肝纤维化与高胰高血糖素血症相关。
Am J Physiol Gastrointest Liver Physiol. 2024 Oct 1;327(4):G558-G570. doi: 10.1152/ajpgi.00147.2024. Epub 2024 Aug 6.
8
Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.超重和肥胖代谢功能障碍相关脂肪性肝病患者极低卡路里生酮饮食 8 周前后肝脂肪变性和纤维化的性别差异。
Nutrients. 2024 May 8;16(10):1408. doi: 10.3390/nu16101408.
9
2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.2024年更新：巴西糖尿病学会关于糖尿病前期或2型糖尿病患者代谢功能障碍相关脂肪性肝病（MASLD）管理的立场
Diabetol Metab Syndr. 2024 Jan 19;16(1):23. doi: 10.1186/s13098-024-01259-2.
10
Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.八周极低卡路里生酮饮食（VLCKD）对超重和肥胖患者代谢功能障碍相关脂肪性肝病（MASLD）的白细胞和血小板计数的影响。
Nutrients. 2023 Oct 21;15(20):4468. doi: 10.3390/nu15204468.
本文引用的文献
1
Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).巴西超重或肥胖成人代谢功能障碍相关脂肪性肝病（MASLD）的筛查、诊断、治疗和随访的循证指南：巴西内分泌学会和代谢学会（SBEM）、巴西肝脏学会（SBH）和巴西肥胖与代谢综合征研究协会（Abeso）的联合立场声明。
Arch Endocrinol Metab. 2023 Nov 27;67(6):e230123. doi: 10.20945/2359-4292-2023-0123.
2
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.超重和肥胖人群中非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球患病率：一项系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.
3
Time trends and projected obesity epidemic in Brazilian adults between 2006 and 2030.2006 年至 2030 年巴西成年人的时间趋势和预计肥胖流行情况。
Sci Rep. 2022 Jul 26;12(1):12699. doi: 10.1038/s41598-022-16934-5.
4
Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.超声检查诊断脂肪肝的准确性和可靠性：一项荟萃分析。
Hepatology. 2011 Sep 2;54(3):1082-1090. doi: 10.1002/hep.24452.
5
The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients.超声在病态肥胖患者肝脂肪变性诊断中的作用。
Obes Surg. 2004 May;14(5):635-7. doi: 10.1381/096089204323093408.
Zotero 插件